BIO Double Helix Sponsor
Sponsors

Company Profile

Colby Pharmaceuticals

Cancer
Urological
CNS

7726 Colony Drive
Suite 04
MADISON, WI 53717
USA
www.colbypharmaceuticals.com 		Incorporated in 2004
6 Employees 		Privately Held

This Year's Highlights

  • 1. Colby becomes Licensee of 3 drug (CPC-100, CPC-200, CPC-300) inhibitors of oxidative stress which are therapeutic Rx's for three different stages of prostate cancer.
  • 2. Colby accesses two NCI grants covering costs for all CPC-100 and CPC-200 IND-enabling data.
  • 3. Colby files patents for CPC-410 & other new chemical entity targeted drugs for metastatic prostate and other therapy resistant cancers as first-line Rxs or in conjunction with current standard of care Rxs.

Anticipated Highlights

  • 2008: Colby anticipates filing CPC-100 IND and initiating Phase I/IIa prostate cancer trial in 2008.

Corporate Mission

The Colby mission is to develop, partner and sell Targeted Oxidative Stress InhibitoRx drugs for the therapeutic treatment of prostate cancer patients.